5 citations
,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
12 citations
,
July 2023 in “Journal of the European Academy of Dermatology and Venereology” Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
March 2026 in “JID Innovations” Aire mutation reduces alopecia areata, while Notch4 mutation prevents it in mice.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
August 2017 in “Academic Commons (Stony Brook University)” Acer1 is essential for skin health and affects hair growth and skin cancer risk.
January 2024 in “Wiadomości Lekarskie” The ABI1 gene contributes to prostate cancer progression and treatment resistance.
October 2021 in “Dermatology Reports” Tofacitinib, a hair regrowth treatment, may worsen acne.
August 2025 in “Nutrients” Ageratum conyzoides extract promotes hair growth and regrowth.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
56 citations
,
December 2011 in “The Plant Journal” AGD1 is important for root hair development in Arabidopsis, working with phosphoinositide signaling and the actin cytoskeleton.
May 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.
January 2024 in “Biomedicines” The review shows that skin symptoms like chronic fungal infections, hair loss, and skin depigmentation are key for early detection and management of APECED.
October 2024 in “Bangladesh Journal of Botany” Figleaf gourd is more resistant to cinnamic acid stress than cucumber.
1 citations
,
January 2025 in “Journal of Cosmetic Dermatology” Inhibiting ACE2 improves skin regeneration during tissue expansion.
Integrating ABI screening in clinics can improve patient care for those at risk of peripheral artery disease.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
May 2017 in “bioRxiv (Cold Spring Harbor Laboratory)” The peach gene pCTG134 helps control the interaction between auxin and ethylene hormones during fruit ripening.
November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
6 citations
,
June 2008 in “Journal of the European Academy of Dermatology and Venereology” A man with Acrodermatitis continua did not get better with etanercept treatment, and his condition worsened, suggesting treatment effectiveness may vary by genetics and race.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
52 citations
,
August 2021 in “Microorganisms” Higher ACE2 levels in certain tissues may worsen COVID-19 in people with other health issues, especially older adults.
38 citations
,
April 2016 in “The Journal of Pathology” Alkaline ceramidase 1 is crucial for healthy skin and energy balance.
11 citations
,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
September 2023 in “Journal of the American Academy of Dermatology” Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
4 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Abrocitinib may help treat alopecia areata effectively with mild side effects.